Journal ArticleDOI
Primary prevention of coronary heart disease: selection of patients for aggressive cholesterol management.
About:
This article is published in The American Journal of Medicine.The article was published on 1999-08-23. It has received 9 citations till now. The article focuses on the topics: Framingham Risk Score & Selection (genetic algorithm).read more
Citations
More filters
Journal ArticleDOI
Kosten-Effektivität der KHK-Prävention
TL;DR: Important principles in health economics are decribed, it was shown that prevention with statins and anti-hypertensive therapy can be cost-effective, as the mortality reduction and hence the increase in life expectancy can be considerable.
Journal ArticleDOI
The hypertension peril: lessons from CETP inhibitors.
TL;DR: In this paper, a review summarizes available clinical and experimental data about potential underlying mechanisms for the effect of cholesteryl ester transfer protein (CETP) inhibition in atherosclerosis.
Journal ArticleDOI
Kosteneffektivität der lipidsenkenden Therapie
TL;DR: Own analyses from the perspective of the social insurance demonstrate that statins are cost-effective in secondary prevention of coronary heart disease (CHD) and cost-effectiveness analyses regarding lipid-lowering therapy are confirmed.
Journal ArticleDOI
Integrating the principles of evidence-based practice: prognosis and the metabolic syndrome.
TL;DR: A hypothetical patient's prognostic concerns are used to depict a practitioner's integration of the principles of evidence-based practice as she considers clinical practice guidelines, expert opinion, and a prognostic study relative to her patient's cancer prognosis.
References
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Prediction of Coronary Heart Disease Using Risk Factor Categories
Peter W.F. Wilson,Ralph B. D'Agostino,Daniel Levy,Albert M. Belanger,Halit Silbershatz,William B. Kannel +5 more
TL;DR: A simple coronary disease prediction algorithm was developed using categorical variables, which allows physicians to predict multivariate CHD risk in patients without overt CHD.
Journal Article
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Anders G. Olsson,Jjv McMurray,Gudmundur Thorgeirsson,C Spaulding,J Slattery,Kalevi Pyörälä,Ole Faergeman,RA Wright,Kåre Berg,Lars Wilhelmsen,Terje R. Pedersen,Tatu A. Miettinen,Harvey D. White,John Kjekshus,Michael Gnant +14 more
Journal ArticleDOI
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Frank M. Sacks,Marc A. Pfeffer,Lemuel A. Moyé,Jean L. Rouleau,John D. Rutherford,Thomas G. Cole,Lisa E. Brown,J. W. Warnica,J. M. O. Arnold,Chuan Chuan C Wun,Barry R. Davis,Eugene Braunwald +11 more
TL;DR: It is demonstrated that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels and was also greater in patients with higher pretreatment levels of LDL cholesterol.
Journal ArticleDOI
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
J. Shepherd,Stuart M. Cobbe,Ian Ford,C. G. Isles,AR Lorimer,Peter W. Macfarlane,J. H. Mckillop,Christopher J. Packard +7 more
TL;DR: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.